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http://www.cancerci.com/content/13/1/107PRIMARY RESEARCH Open AccessFPGS rs1544105 polymorphism is associated with
treatment outcome in pediatric B-cell precursor
acute lymphoblastic leukemia
Shu-Guang Liu, Chao Gao, Rui-Dong Zhang, Ying Jiao, Lei Cui, Wei-Jing Li, Zhen-Ping Chen, Min-Yuan Wu,
Hu-Yong Zheng, Xiao-Xi Zhao, Zhi-Xia Yue and Zhi-Gang Li*Abstract
Background: Folypolyglutamate synthase (FPGS) catalyzes the polyglutamation of folates and antifolates, such as
methotrexate (MTX), to produce highly active metabolites. FPGS tag SNP rs1544105C > T is located in the gene
promoter. The aim of the present study was to investigate the impact of rs1544105 polymorphism on the
treatment outcome in pediatric B-cell precursor acute lymphoblastic leukemia (BCP-ALL).
Methods: This study enrolled 164 children with BCP-ALL. We genotyped the FPGS SNP rs1544105, and analyzed the
associations between its genotypes and treatment outcome. We also examined FPGS mRNA levels by real-time PCR
in 64 of the 164 children, and investigated the function of this polymorphism on gene expression.
Results: We found significantly poor relapse-free survival (RFS) (p = 0.010) and poor event-free survival (EFS) (p = 0.046)
in carriers of CC genotype. Multivariable Cox regression analyses adjusted for possible confounding variables showed
that, relative to the CT + TT genotypes, the CC genotype was an independent prognostic factor for poor RFS (hazard
ratio [HR], 4.992.; 95% CI, 1.550-16.078; p = 0.007). No association was found between any toxicity and rs1544105
polymorphism. Quantitative PCR results showed that individuals with the T allele had lower levels of FPGS transcripts.
Conclusions: Our study indicates that FPGS rs1544105C > T polymorphism might influence FPGS expression and affect
treatment outcome in BCP-ALL patients.
Keywords: Folypolyglutamate synthase (FPGS), Methotrexate (MTX), Polymorphism, Treatment outcome,
Acute lymphoblastic leukemia (ALL)Background
Cure rates for childhood acute lymphoblastic leukemia
(ALL) have exceeded 80%. However, for the 15-20% of
children with newly diagnosed ALL who will ultimately re-
lapse, traditional risk assessment remains inadequate [1].
Multiple studies have suggested that the outcome in child-
hood ALL may be affected by how rapidly and effectively
an individual patient metabolizes certain chemotherapeu-
tic agents [2]. Thus, if the germline polymorphisms in
drug-metabolism genes were better defined, tailored drug* Correspondence: ericlzg70@hotmail.com
Hematology Oncology Center, Beijing Key Laboratory of Pediatric
Hematology Oncology, National Key Discipline of Pediatrics, Beijing
Children’s Hospital, Capital Medical University, 56 Nanlishi Road, 100045
Beijing, China
© 2013 Liu et al.; licensee BioMed Central Ltd.
Commons Attribution License (http://creativec
reproduction in any medium, provided the ortherapy based on these factors might further improve
outcome.
Methotrexate (MTX) is a major component in all
contemporary treatment protocols for childhood ALL.
High-dose MTX (HDMTX) is associated with an improved
outcome in ALL patients. Despite its clinical success, MTX
may lead to several toxicities in a considerable number of
patients [3,4]. Folypoly-γ-glutamate synthetase (FPGS) is
responsible for the activation of MTX to MTX polygluta-
mates (MTXPGs). Loss of FPGS activity is an established
mechanism of resistance to MTX in vitro and in vivo [5-7].
FPGS activity is significantly correlated with FPGS mRNA
levels [8]. Overexpression of FPGS has been associated
with increased sensitivity of several glioma cell lines to
MTX [9]. In addition, altered FPGS expression was found
associated with outcome of colorectal cancer patients [10].This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Table 1 Baseline characteristics of patients with BCP-ALL
(N = 164)
Characteristics N (%)



















CNS involvement 2 (1.2)
Event
Relapse 16 (9.8)
Isolated BM 13 (7.9)
Isolated CNS 1 (0.6)





BCP-ALL, B-cell precursor ALL; WBC, white blood cell count; SR, standard-risk;
MR, medium-risk; HR, high-risk; BM, bone marrow; CNS, central nervous
system. *4 patients died of severe infections during induction.
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http://www.cancerci.com/content/13/1/107In childhood ALL, a strong correlation exists between
FPGS expression, intracellular MTXPGs accumulation and
treatment outcome [8,11].
Up to now, there have been a few reports on the clin-
ical importance of polymorphisms in FPGS gene [12-14].
However, its clinical role in childhood ALL remains to
be defined. FPGS rs1544105 C > T is a tag SNP through
HapMap database (release #27) in the promoter of FPGS
gene. It is reported that FPGS rs1544105 C allele was as-
sociated with MTX poor response [13,14]. Panetta et al.
found that rs1544105 polymorphism showed a signifi-
cant relation to FPGS activity in childhood ALL [15]. So
we hypothesized that rs1544105 might have important
clinical roles in childhood ALL.
In the present study, we investigated the role of FPGS
rs1544105 polymorphism in treatment outcome in chil-
dren with newly diagnosed B-cell precursor ALL (BCP-
ALL) and its influence on FPGS expression.
Results
Patient characteristics and FPGS genotyping
The main clinical characteristics of the 164 patients are
shown in Table 1. FPGS rs1544105 genotype distribu-
tion is as follows: 14 CC (8.6%), 75 CT (45.7%), 75 TT
(45.7%). Allele frequencies were in close agreement with
values previously reported [13] and were in Hardy-
Weinberg equilibrium (χ2 = 0.620, p = 0.431). In our
study, rs1544105 genotypes had no association with the
common clinical indices (Table 2).
FPGS rs1544105 T allele might cause decreased
mRNA levels
As rs1544105 polymorphism is located in FPGS promoter,
this polymorphism might impact the expression of FPGS.
Therefore, we examined FPGS mRNA levels by real-time
PCR in 64 children who had ≥70% leukemic cells in diag-
nostic bone marrow samples and sufficient cDNA for
analysis, and whose FPGS rs1544105 genotypes were de-
termined. As shown in Figure 1, we found that the FPGS
rs1544105 T variant was associated with a relatively lower
mRNA level. Average expression of patients harboring the
CC genotype was approximately 1.5 times higher than
CT (p = 0.041) and TT (p = 0.031) carriers. No significant
differences were detected between CT and TT groups. In
addition, FPGS mRNA expression had no association with
gene fusions (Additional file 1: Table S1).
FPGS rs1544105 polymorphism and treatment outcome
Given that rs1544105 polymorphism might influence FPGS
mRNA levels, and altered FPGS expression was found as-
sociated with outcome of colorectal cancer patients [9], we
analyzed the correlation between FPGS rs1544105 geno-
types and outcomes in 164 patients. Figure 2 showed the
effects of rs1544105 polymorphism on treatment outcome.There was a significantly higher relapse rate in CC group
compared with CT + TT carriers (CC: 28.6%, CT + TT:
8.0%; χ2: p = 0.034). A poor RFS was found in the CC group
(log rank: p = 0.010), as well as a poor EFS (log rank: p =
0.046). Multivariate survival analysis showed that the
rs1544105 CC genotype was an independent prognosis fac-
tor for poor RFS (HR, 4.992; 95% CI, 1.550-16.078; p =
0.007) compared with the CT + TTgenotypes (Table 3).
FPGS rs1544105 polymorphism and MTX-related toxicity
FPGS is responsible for the activation of MTX to MTXPGs
and higher MTXPGs level is associated with increased
toxicity [4]. Given that rs1544105 polymorphism might
influence FPGS mRNA levels, so we next analyze the
Table 2 The association between FPGS rs1544105
genotypes and patient characteristics (N = 164)
Characteristics FPGS SNP rs1544105 p-value*
CC CT + TT
genotype genotype
Gender 1.000
Male 9 (62.3) 95 (63.3)
Female 5 (35.7) 55 (36.7)
Age (years) 0.336
<1 0 0
1-9 13 (92.9) 123 (82.0)
≥10 1 (7.1) 27 (18.0)
Treatment group 0.797
SR 4 (28.6) 58 (38.7)
MR 8 (57.1) 73 (48.7)
HR 2 (1.3) 19 (12.6)
WBC (109/L) 0.710
<50 11 (78.6) 125 (83.3)
≥50 3 (21.4) 25 (16.7)
TEL-AML1 0.770
Positive 3 (21.4) 38 (25.3)
Negative 11 (78.6) 112 (74.7)
E2A-PBX1 1.000
Positive 1 (7.1) 15 (10.0)
Negative 13 (92.9) 135 (90.0)
BCR-ABL 0.141
Positive 2 (14.3) 6 (4.0)
Negative 12 (85.7) 144 (96.0)
MLL-AF4 1.000
Positive 0 1 (0.6)
Negative 14 (100.0) 149 (99.4)
Prednisone response 0.164
Good 1 (7.1) 1 (0.6)
Poor 13 (92.9) 149 (99.4)
CNS involvement 1.000
Absent 14 (100.0) 148 (98.7)
Present 0 2 (1.3)
*Data were calculated by χ2 test. WBC, white blood cell count; SR, standard-
risk; MR, medium-risk; HR, high-risk; CNS, central nervous system.
Figure 1 The rs1544105 polymorphism influences mRNA levels
of FPGS. The expression level of FPGS was analyzed by quantitative
RT-PCR and was normalized using ABL as reference gene. Data are
shown as mean ± SEM.
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related toxicities during consolidation therapy. As the HR
group was treated with HD-MTX and other chemothera-
peutic drugs, for example Dexamethasone, Vincristine,
Cyclophosphamide, Cytarabine, L-asparaginase, which may
influenced the assessment of MTX toxicity, only 139 pa-
tients enrolled in SR and MR treatment groups were evalu-
able for the toxicity analysis. As shown in Table 4, resultsshowed that there was no correlation between any toxicity
and rs1544105 genotypes, calculated by χ2 test.
Discussion
In the present study, we investigated whether FPGS
rs1544105C >T polymorphism was associated with treat-
ment outcome among childhood BCP-ALL patients. We
found that CC genotype is significantly associated with
poor RFS (p = 0.010) and EFS (p = 0.046) compared with
the CT and TT genotypes. Furthermore, in multivariate
Cox regression analysis, we found that the FPGS rs1544105
is an independent prognostic factor for RFS. Patients carry-
ing the rs1544105 CC genotype displayed a higher risk of
relapse than CT + TTgenotypes (HR, 4.992; 95% CI, 1.550-
16.078; p = 0.007), indicating that rs1544105 polymorphism
is a potential predictor for survival in childhood BCP-ALL.
Two previous studies reported that FPGS rs1544105 C al-
lele was associated with MTX poor response in rheumatoid
arthritis (RA) patients in north Indians [13,14], which were
in line with our finding. To our knowledge, this is the first
report that FPGS rs1544105 is associated with outcome in
pediatric ALL, which extended our understanding of the
role of FPGS in MTX response.
Previous observations suggested that FPGS downregula-
tion leads to resistance to MTX and novel antifolates in
some cancer cell lines [5,6,16,17]. As rs1544105 T allele
carriers had lower FPGS mRNA level, it seems that they
Figure 2 The prognostic significance of FPGS rs1544105 in 164 BCP-ALL patients treated according to CCLG-ALL 2008 protocol. The
solid line was derived from the patients carrying CC genotype, dotted line from patients carrying CT and TT genotypes. There were different RFS
(left, p = 0.010, by log-rank test) and EFS (right, p = 0.046, by log-rank test) between the two groups.
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sis. However, our data suggested that T allele carriers had
better RFS and EFS than CC genotype carriers, which ap-
pears to be in contrast with previous results. In fact, FPGS
modulation affects both polyglutamylation of antifolatesTable 3 Multivariate Cox-regression analysis for RFS and EFS






















CT + TT 1 Reference
CC 4.992 1.550-16.078
*Data were calculated by Cox-regression analysis. BCP-ALL, B-cell precursor ALL; RFS
CNS, central nervous system; HR, hazard ratio; 95% CI, 95% confidence interval.and folate cofactors [18-20]. Cho et.al reported that FPGS
modulation on the chemosensitivity of breast cancer cells
to MTX depends not only on MTX polyglutamylation but
also on polyglutamylation of intracellular folate pools. So
it is possible that FPGS rs1544105 T allele carriers hadin patients with BCP-ALL (N = 164)
Multivariable analysis for EFS
p* HR 95% CI p*
- 1 Reference -
0.847 0.300 0.036-2.466 0.244
- 1 Reference -
0.003 3.745 1.062-13.204 0.072
- 1 Reference -
0.118 2.701 0.497-14.681 0.250
- 1 Reference -
0.104 0.316 0.038-2.629 0.059
- 1 Reference -
0.257 3.890 0.877-17.248 0.222
- 1 Reference -
0.001 11.375 1.487-86.991 0.019
- 1 Reference -
0.007 2.723 0.766-9.674 0.059
, relapse free survival; EFS, event free survival; WBC, white blood cell count;
Table 4 The relationships between FPGS rs1544105
genotypes and MTX-related toxicity (SR and MR, N = 139)
Toxicity FPGS SNP rs1544105 p-value*
CC (n,%) CT + TT (n,%)
Oral mucositis
With 1 (8.3) 11 (8.7) 0.969
Without 11 (91.7) 116 (91.3)
Skin toxicity
With 1 (8.3) 10 (7.9) 0.955
Without 11 (91.7) 117 (92.1)
Hepatic toxicity
With 0 (0) 17 (13.4) 0.176
Without 12 (100.0) 110 (86.6)
Anemia
With 6 (50.0) 52 (40.9) 0.543
Without 6 (50.0) 75 (59.1)
Neutropenia
With 6 (50.0) 77 (60.6) 0.473
Without 6 (50.0) 50 (39.4)
Thrombocytopenia
With 2(16.7) 25 (19.7) 0.801
Without 10 (83.3) 102 (80.3)
*Data were calculated by χ2 test.
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type carriers, and consequently, increase in polyglutamyla-
tion of intracellular folate cofactors may diminish or even
abolish the effects of decrease in polyglutamylation of
antifolates. This might lead to enhanced chemosensitivity
and better survival in T allele carriers. The differences of
folate concentrations between T allele carriers and CC
genotype carriers should be determined in the future.
Treatment-related toxicity can not only be life threaten-
ing, but is also one of the main reasons for interruption or
discontinuation of chemotherapy, which may increase re-
lapse risk [8,21]. Two previous studies reported that FPGS
rs1544105 C allele was associated with MTX poor re-
sponse in rheumatoid arthritis (RA) patients in north In-
dians [13,14]. In our study, no significant association was
revealed between this polymorphism and any toxicity. The
differences may result from our limited samples.
SNPs in gene regulatory region that alter the expression
or function of proteins targeted by drugs can contribute
significantly to variation in the responses of individuals.
The rs1544105 is located in the promoter of FPGS gene, so
we hypothesized that this polymorphism may affect treat-
ment outcome by influencing FPGS mRNA expression.
Among the164 genotyped patients, we analyzed the mRNA
levels of 64 patients. We found that rs1544105 genotypes
were correlated with mRNA levels of FPGS. The T allele
carriers (CT + TT) had lower mRNA expression comparedwith CC genotype. Panetta et al. reported that FPGS activ-
ity of rs1544105 CC carriers was 2.6 times higher than CT
and TT carriers in a St Jude ALL cohort [15]. As FPGS
mRNA expression correlates with activity [8], their results
were in agreement with ours. In order to understand the
mechanism underlying the altering expression, we investi-
gated the sequence for putative transcription factors bind-
ing sites using TRAP [22]. The studied SNP rs1544105
was located within a predicted binding site for cAMP
response element-binding protein (CREB) transcrip-
tion factors, and to modulate the binding affinity of
CREB, with higher affinities predicted for the C-allele.
CREB is a transcription factor that regulates gene
expression principally through activation of the cyclic
AMP (cAMP)-dependent cell signal transduction pathways
by binding to the cAMP response element (CRE) region at
the promoters. CREB is reported to be overexpressed in
childhood ALL and be critical in leukemogenesis [23]. Fur-
ther experiments are needed to reveal the detailed molecu-
lar mechanisms.
No statistical association was found between rs1544105
polymorphism and any clinical indices. It was reported that
patients with TEL-AML1 and E2A-PBX1 fusion genes had
significantly lower level of FPGS mRNA expression in
childhood ALL. And TEL-AML1 and E2A-PBX1 can
downregulate FPGS promoter activity and lead to lower
mRNA expression and enzymatic activity [24,25]. As
rs1544105 influences FPGS expression, we supposed that
this polymorphism might correlate with TEL-AML1and
E2A-PBX1 fusions. However, we found no association
between rs1544105 and TEL-AML1 (p = 0.071) and E2A-
PBX1 (p = 0.601) fusions. Neither did we found any associ-
ation between FPGS mRNA level and TEL-AML1 (p =
0.070) and E2A-PBX1 (p = 0.198) fusions. The difference
may result from our limited samples. But our data sug-
gested that TEL-AML1+ patients had lower FPGS mRNA
expression than TEL-AML1- ones (Additional file 1: Table
S1), which was in agreement with previous results.
Conclusions
FPGS rs1544105C > T polymorphism may influence the
expression of FPGS and be associated with treatment out-
come in childhood BCP-ALL. Larger prospective studies
should be undertaken to confirm our recent results. In




The criterion for patient inclusion in this study was newly
diagnosed BCP-ALL patients who had at least 3-year
follow-up time till March 2013 and sufficient DNA sam-
ples. Based on this criterion, 164 children enrolled during
March 2008 to March 2010 and treated according to
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protocol were collected in our study. All subjects were
unrelated ethnic Chinese (aged 1.0-15.0 years, median
4.0 years). The common clinical characteristics of 164
patients were shown in Table 1. The median follow-up
time was 48.0 months (range, 2.0 to 59.0) with 13 patients
suffered bone marrow relapse, 1 suffered isolated central
nervous system (CNS) relapse, 2 suffered isolated testis re-
lapse, 4 died of severe infections during induction, 7 lost
follow-up, and 137 cases were in continued complete re-
mission (CCR).
Patients were stratified into standard-risk, medium-risk
and high-risk treatment groups (SR, MR and HR) accord-
ing to age, white blood cell count (WBC) in peripheral
blood, immunophenotype, fusion gene, karyotype, CNS sta-
tus, prednisone response, day 15 and day 33 BM remission
status, minimal residue disease (MRD) on day 33 and at
day 78, etc. (Additional file 2: Table S2). Sixty-two (37.8%)
patients were assigned to SR group, 81 (49.4%) to MR
group, and 21 (12.8%) to HR group (Table 1). Each group
of patients received different treatment regimens. The de-
tails of treatment during the consolidation period are out-
lined in Additional file 3: Table S3. Doses of MTX differed
by different treatment branch: the standard-risk (SR) group
received 2 g/m2, while the medium- risk (MR) and high-
risk (HR) groups received 5 g/m2. In addition, Non-HR
(SR and MR) patients received oral 6-mercaptopurine (6-
MP) and HR patients received other drugs concurrently.
Leucovorin rescue was given at 42 h, 48 h and 54 h from
the start of MTX infusion. Of the 164 patients in this
study, 139 were enrolled into the analysis of association
between FPGS SNP rs1544105 polymorphism and MTX-
related toxicity during consolidation therapy. There were a
total of 25 patients not analyzed for MTX-related toxicity,
including 4 patients who died before consolidation therapy,
and 21 HR patients who were treated with HD-MTX and
other chemotherapeutic drugs, for example Dexamethasone,
Vincristine, Cyclophosphamide, Cytarabine, L-asparaginase,
which may influenced the assessment of MTX toxicity.
Bone marrow (BM) samples of patients were collected
at diagnosis. Monouclear cell separation was carried out
as previously described [4,26,27] and cells were immedi-
ately stored at −70°C until use. This study was approved
by the BCH Institutional Ethics Committee and informed
consent according to the Declaration of Helsinki was
signed by the guardians of the patients.
DNA extraction and SNP genotyping
Genomic DNA was extracted using a Genomic DNA
Isolation Kit (U-gene, Anhui, China). Genotypes of the
FPGS SNP rs1544105 were determined by PCR-RFLP
methods [14]. FPGS rs1544105 primer sequences were
forward: 5′-GTGCCTCCTTCACACACAG-3′and re-
verse: 5′-CCCAGAGTCCTTATTCTTAGCC-3′. PCRproducts were digested with HpyCH4IV (New England
BilLabs, Inc, Beverly, MA) and separated on 10% poly-
acrylamide gel. A 10% random sample (n = 17) of the
cases was verified by directly DNA sequencing of the
PCR products.
RNA extraction and FPGS expression analysis
The criterion for patient inclusion in expression analysis
was ≥70% leukemic cells in diagnostic bone marrow sam-
ples and sufficient cDNA for analysis. Sixty-four patients
among the 164 BCP-ALL genotyped in this study met this
criterion and were included for a quantitative RNA expres-
sion assay. Total RNA from mononuclear cells was isolated
using Trizol reagent (Invitrogen, Paisley, UK). The mRNAs
were reverse-transcribed into cDNAs using random hexam-
ers and moloney murine leukemia virus reverse transcript-
ase according to the manufacturer’s instructions (Promega,
Madison, USA). The mRNA expression level of FPGS was
measured by real-time quantitative reverse transcription-
PCR using the ABI PRISM 7500 Sequence Detection Sys-
tem (Applied Biosystems, Singapore) based on the SYBR
Green method. The ABL gene was used as the internal
control, as suggested by the Europe Against Cancer pro-
gram [28]. The primer sequences used for FPGS PCR were
forward: 5′-CCCCGAGGTTCGAGTCTTG-3′ and reverse:
5′-GTCACTGTGAAGTTCTGTTGGTCTG-3′; and the
primer sequences used for ABL were forward: 5′-TGGA
GATAACACTCTAAGCATAACTAAAGGT-3′ and reverse:
5′-GATGTAGTTGCTTGGGACCCA-3′. The PCR reac-
tions were performed in a total volume of 25 μl, including
12.5 μl of 2 × SYBR® Green PCR Master Mix (Applied Bio-
systems), 2 μl of cDNA, and 1 μl of primer mix (10 μM
each). The PCR program was as follows: 95°C for 10 minutes,
40 cycles of 95°C for 15 seconds, 60°C for 1 minute, and a
final step for generation of a dissociation curve to assess the
specificity of the amplified products. Relative quantification
analysis was performed using the comparative CT method
(2-△△CT). Reactions were in triplicate in three independent
experiments.
Toxicity
Toxicities were graded according to the NCI Common
Toxicity Criteria version 1.0. Hematological toxicity (anemia,
thrombocytopenia, neutropenia) and non-hematological tox-
icity (skin toxicity, oral mucositis, and hepatic toxicity which
means transaminase levels > 2 times as high as normal limit)
were included. The highest grade of toxicity observed in each
patient during the consolidation therapy period was re-
corded. No patients died from toxicity.
Statistical analysis
The allele frequencies of polymorphisms were tested for
Hardy-Weinberg equilibrium using the Chi-square (χ2)
test. Toxicities were represented by the value 1or 0,
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ing the MTX course. χ2 test was used to determine the re-
lationship between rs1544105 genotypes with toxicity,
outcome and other clinicobiological characteristics. Re-
lapse was defined as the reappearance of leukemic cells in
BM (>5% blasts) and/or the reappearance of clinical evi-
dence of the disease. Relapse-free survival (RFS) was de-
fined as the time from CR to the date of relapse, censored
at date of last time of contact or death in remission. The
duration of event-free survival (EFS) was defined from the
date of diagnosis to the date of relapse or death, or the last
contact with patients in continuous hematologic CR. The
probability of RFS and EFS were estimated using the
Kaplan–Meier method and univariate associations between
rs1544105 genotypes were compared by log-rank tests.
Multivariate Cox regression models adjust for potential
confounding variables were used to analyze the prognostic
significance of rs1544105 genotypes. All statistical analyses
were 2 tailed and performed with SPSS 16.0 for Windows.
P value less than 0.05 were considered significant.
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